Surya Singh, MD: The timeliness of therapy and how payers ensure that patients get access early to treatment for SMA [spinal muscular atrophy] is 1 of the thorniest questions that everyone, all stakeholders, are wrestling with. It’s not only payers too. I’ll broaden it for a second and then zero in on the payer perspective and how managed care deals with it. But, timeliness is incredibly important here because we’re trying to prevent deterioration. You’re trying to allow these patients, these infants, to continue to march on toward motor milestones they wouldn’t otherwise achieve without treatment. That’s the point of all of this, and I don’t think any of us want to lose sight of that. Earlier treatment from the day that it’s available and conferring with experts is really important.
Two complications have emerged that I think everyone is still grappling with. One is that the differential diagnosis can be very broad. Until there’s either a mandated screening that takes place, so we know when people have the deletions that lead to the disease to start off with, we’re left with when these symptoms start to show up and patients are missing motor milestones. It can mimic lots of other things, then what happens in that diagnostic process? I would say just before I zero in on the payer issues that that time to diagnosis is still probably the most important thing. Just looking at it globally, that dictates the timing of treatment. This is because, is the diagnosis suspected, or does the person say, “This is just a baby who is a little floppy and hasn’t hit their milestones and is still in the range of normal or has a different sort of clinical presentation”?
That aside for a second, once the request has been made now, the diagnosis is in site, and the payer is involved, the payers are trying to do a couple of things…these are activities that are relevant to SMA but also more probably for a prior authorization [PA].
One is that there are a lot of effort and resources going into the electronic extraction of the necessary data to fulfill the PA criteria behind the scenes. The doctor submits their request or is notified that a PA is required, and all of the data that’s needed to confirm that this patient is appropriate for treatment—according to the medical policy that the payer has in place—is fulfilled without the treating physician and his or her staff having to do anything else. That’s the future; that is where a lot of resources are going. I think payers are increasingly making progress on that path to be able to get that stage.
That said, that’s not the norm right now, especially when there are specific laboratory values that are required and so on. Rare disorders get an expedited review, in most cases from payers, because obviously timeliness is of the essence here. However, the delays are typically when there’s “additional information required,” and most often clinical documentation is the additional information they’re looking for. There is a lag when that additional information is part of the policy and the person doing the review says, “I can’t make a rendered decision until I get that,” and then we can see delays of up to 10 days. That is like an eon when you’re talking about families dealing with it.
NCCN Guidelines Update Adds Momelotinib Below Ruxolitinib for High-, Low-Risk Myelofibrosis
January 23rd 2024Momelotinib was given category 2A and 2B status for patients with high- and low-risk myelofibrosis (MF) and MF with anemia. However, ruxolitinib retains a higher category of recommendation as a treatment for patients with MF.
Read More
Oncology Onward: A Conversation With Dr Shereef Elnahal, Under Secretary for Health
April 20th 2023Shereef Elnahal, MD, MBA, under secretary for health at the Veterans Health Administration (VHA), sat for a conversation with our hosts Emeline Aviki, MD, MBA, Memorial Sloan Kettering Cancer Center, and Stephen Schleicher, MD, MBA, Tennessee Oncology, that covered the cancer footprint of the VHA.
Listen
Interventions Needed to Increase DMT Uptake in Sickle Cell Disease
December 26th 2023A recent study found that uptake of disease-modifying therapies (DMTs) has been low among patients with sickle cell disease, suggesting that more interventions that consider individual patient characteristics are needed to improve adoption.
Read More
Exploring Payer Coverage Decisions Following FDA Novel Drug Approvals
May 3rd 2022On this episode of Managed Care Cast, Ari D. Panzer, BS, lead author and researcher, then at Tufts Medical Center—now at Duke University—discusses the findings from his team’s investigation into coverage decisions by health plan insurers of the 66 drugs approved by the FDA in 2018.
Listen
Exagamglogene Autotemcel Meets End Points in Severe Sickle Cell Disease, β-Thalassemia
December 7th 2023Two posters set to be presented at the 65th American Society of Hematology Annual Meeting & Exposition met their primary and secondary end points regarding exagamglogene autotemcel therapy for sickle cell disease and β-thalassemia.
Read More
NCCN Guidelines Update Adds Momelotinib Below Ruxolitinib for High-, Low-Risk Myelofibrosis
January 23rd 2024Momelotinib was given category 2A and 2B status for patients with high- and low-risk myelofibrosis (MF) and MF with anemia. However, ruxolitinib retains a higher category of recommendation as a treatment for patients with MF.
Read More
Oncology Onward: A Conversation With Dr Shereef Elnahal, Under Secretary for Health
April 20th 2023Shereef Elnahal, MD, MBA, under secretary for health at the Veterans Health Administration (VHA), sat for a conversation with our hosts Emeline Aviki, MD, MBA, Memorial Sloan Kettering Cancer Center, and Stephen Schleicher, MD, MBA, Tennessee Oncology, that covered the cancer footprint of the VHA.
Listen
Interventions Needed to Increase DMT Uptake in Sickle Cell Disease
December 26th 2023A recent study found that uptake of disease-modifying therapies (DMTs) has been low among patients with sickle cell disease, suggesting that more interventions that consider individual patient characteristics are needed to improve adoption.
Read More
Exploring Payer Coverage Decisions Following FDA Novel Drug Approvals
May 3rd 2022On this episode of Managed Care Cast, Ari D. Panzer, BS, lead author and researcher, then at Tufts Medical Center—now at Duke University—discusses the findings from his team’s investigation into coverage decisions by health plan insurers of the 66 drugs approved by the FDA in 2018.
Listen
Exagamglogene Autotemcel Meets End Points in Severe Sickle Cell Disease, β-Thalassemia
December 7th 2023Two posters set to be presented at the 65th American Society of Hematology Annual Meeting & Exposition met their primary and secondary end points regarding exagamglogene autotemcel therapy for sickle cell disease and β-thalassemia.
Read More
2 Commerce Drive
Cranbury, NJ 08512